Please type a plus sign (+) inside this box -> -	\mp
--	-------

Substitute for form 1449A/B/PTO				Complete if Known		
				Application Number	10/588,323	
INFORMATION DISCLOSURE				Filing / 371(c) Date	February 16, 2007	
STATEMENT BY APPLICANT (Use as many sheets as necessary)				First Named Inventor	MAGILAVY	
			PLICANT	Group Art Unit	1644	
			cessary)	Examiner Name	Phillip Gambel	
Sheet	1	of	1	Attorney Docket Number	253780	

OTHER - NON PATENT LITERATURE DOCUMENTS							
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation *				
	C624	JEFFERIS et al., IgG-Fc-medicated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation, <i>Immunological Reviews</i> 1998, 163: 59-76 (June 1998)					
	C625	JANEWAY et al., <i>Immunobiology, The immune system in health and disease, Third Edition</i> , Current Biology Ltd./Garland Publishing Inc., New York, pp. 7:4-7:7 (1997)					

1 - (1) (1) - (1)							

Examiner Signature	/Phillip Gambel/	Date Considered	04/02/2009

^{*} If the reference is not in English, then at least one of the following is provided: (a) an English translation in whole or in part or (b) a concise statement of relevance in the form of, for example, an English language counterpart, an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.G./